Skip to content

DrugPatentWatch - Transform Data into Market Domination

Business Intelligence on Biologic and Small Molecule Drugs

Blog Home
DrugPatentWatch Home
Pricing
About
Contact

DrugPatentWatch - Transform Data into Market Domination

Business Intelligence on Biologic and Small Molecule Drugs

Blog Home
DrugPatentWatch Home
Pricing
About
Contact

Drug Patent Expirations for the Week of July 5, 2026

By / July 8, 2026

Copyright © DrugPatentWatch. Originally published at https://www.drugpatentwatch.com/blog/

TRIKAFTA (COPACKAGED) (elexacaftor, ivacaftor, tezacaftor; ivacaftor)

Vertex pharms inc Patent: 8,354,427 Expiration: Jul 6, 2026

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com

Make Better Decisions with DrugPatentWatch

» Start Your Free Trial Today «

Copyright © DrugPatentWatch. Originally published at

Related Posts:

The Global Patent Thicket: A Comparative Analysis of…
The BTD Paradox: How Accelerated Approval Reshapes…
Using Drug Patents to Block Competitors: The Tactics…
The Global Generic Drug Market: Trends,…
What the Most Successful Drug Launches Reveal About…
CDMO Project Management: Tips and Tricks for Success
Can Drug Companies Bribe the FDA? Unveiling the…
AI-Driven Drug Discovery: Transforming the Landscape…
CDMO Selection: The Ultimate Checklist
Real World Blockchain Uses in the Pharmaceutical Industry
M&A in Generic Drug Development: IP Valuation,…
The Great Pharmaceutical Pivot: Navigating Strategy,…
Overnight Millionaires or a Decade-Long Marathon?…
Exploring the Role of South Africa in the Global…
Mastering Strategic Decision-Making in the…
Russia Patent-Term Extensions: What Every Pharma IP…
Strategies to Maximize Product Value Amid Loss of…
PBMs, Formularies, and Rebates: What Investors Should Know
Unlocking the Potential of Abandoned and Expired…
Predict The Patent Cliff: The Patent Cliff Is…
Read the Clock Right: Mapping Regulatory…
How Financial Analysts Use Drug Patent Expiry Data…
India's Growing Importance in Generic Drug API Manufacturing
Patent Expiration Data: The Procurement Playbook…

Exelixis, Inc. v. Handa Pharmaceuticals, Inc.

Amneal Pharmaceuticals LLC v. Alembic Pharmaceuticals Ltd.

Related Posts

Drug Patent Expirations for the Week of January 4, 2026

Patent Expiration / By

Drug Patent Expirations for the Week of January 18, 2026

Patent Expiration / By

Make Better Decisions

See Plans & Pricing

Recent Posts

Amneal Pharmaceuticals LLC v. Alembic Pharmaceuticals Ltd.
Exelixis, Inc. v. Handa Pharmaceuticals, Inc.
TAKEDA PHARMACEUTICALS U.S.A., INC. v. SUN PHARMACEUTICAL INDUSTRIES LTD.
Azurity Pharmaceuticals, Inc. v. Aurobindo Pharma Limited
Vertex Pharmaceuticals Incorporated v. Squires

Popular Posts

Bio-Betters Are Eating Biosimilars: The $150B Patent Strategy Reshaping Biologic Competition
NCE Exclusivity Decoded: The Five-Year Clock, the NCE-1 Date, and Who Wins the Generic Race
AI-Driven Drug Discovery: Transforming the Landscape of Pharmaceutical Research
A Definitive Guide to Valuing Pharmaceutical and Biotech Companies
TAKEDA PHARMACEUTICALS U.S.A., INC. v. SUN PHARMACEUTICAL INDUSTRIES LTD.
The Price Control Playbook: A Strategic Analysis of Generic Drug Pricing in Major Emerging Markets
Azurity Pharmaceuticals, Inc. v. Aurobindo Pharma Limited
Vertex Pharmaceuticals Incorporated v. Squires
Drug Patent Lifecycle: The Complete Pharma IP Strategy Playbook
CDMO Pricing: The Total Cost of Ownership Playbook for Pharma IP Teams and Portfolio Managers

Copyright © 2026 DrugPatentWatch - Transform Data into Market Domination

DrugPatentWatch - Transform Data into Market Domination

Subscribe to Free Updates

Sign in or create a free account to read this DrugPatentWatch article

Sign in or create a free account to read this DrugPatentWatch article

EmailEnter your email address